Our results indicate that Fe-EGCG@RSL3 is a multifaceted nanoparticle platform that not only directly induces tumor cell ferroptosis but also enhances the efficacy of anti-PD1-based immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.